RARE Daily

Gene Therapy Developer Generation Bio Raises $196 Million in Public Offering

January 7, 2021

Rare Daily Staff

Gene therapy developer Generation Bio raised $196 million through the pricing of a public offering of 8 million shares of its common stock at $24.50 per share.

In addition, the company has granted the underwriters a 30-day option to purchase up to 1.2 million additional shares of common stock at the public offering price, less the underwriting discount and commissions.

Generation Bio is developing a non-viral gene therapy platform that overcomes the immunogenicity associated with viral-vector gene therapies, which has historically limited the number of patients that can be treated and prevented re-dosing. Its preclinical pipeline targets genetic diseases of the retina, central nervous system, and lungs. The company’s lead program addresses rare lung diseases.

The company’s non-viral platform is designed to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.


Stay Connected

Sign up for updates straight to your inbox.